insulin and lipid panels
These findings were accompanied by meaningful improvements in cardiometabolic markers including waist circumference, blood pressure, fasting glucose, HbA1c, insulin levels, and lipid profiles
These changes may be linked to: Altered saliva composition Digestion shifts Subtle changes in sensory signaling When taste perception shifts, even mild flavors can seem off or unpalatable, and foods once enjoyed may trigger nausea or aversions
The only valid in-use shelf life is that stated on the IMP label or trial protocol
Common experiences: Occasional mild GI symptoms, stable energy, reduced food noise, feeling normal on medication
Retatrutide remains an experimental medication still in Phase 3 clinical trials